1. Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19  CP24 Toronto's Breaking News
  2. Emergent to make Calgary-based Providence Therapeutics' potential COVID-19 vaccine  CBC.ca
  3. Providence licenses mRNA technology to China's Everest in $100-million deal  Financial Post
  4. Deal struck for Winnipeg facility to produce COVID-19 vaccine  Winnipeg Sun
  5. 'Abysmal': Canadian COVID vaccine maker slams feds on lack of support  BNN
  6. View Full coverage on Google News
Calgary-based Providence Therapeutics says it has signed two contracts to have its developmental mRNA vaccine for COVID-19 manufactured in Canada.Calgary-based Providence Therapeutics says it has signed two contracts to have its developmental mRNA vaccine for COVID-19 manufactured in Canada.

Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19 | CP24.com

Calgary-based Providence Therapeutics says it has signed two contracts to have its developmental mRNA vaccine for COVID-19 manufactured in Canada.Calgary-based Providence Therapeutics says it has signed two contracts to have its developmental mRNA vaccine for COVID-19 manufactured in Canada.

Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19 - Canada News - Castanet.net

Emergent BioSolutions Inc. signed a five-year agreement with Calgary-based biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.Emergent BioSolutions Inc. signed a five-year agreement with Calgary-based biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

www.cbc.ca

Calgary-based Providence has secured rights to stock and profit sharing totalling up to $400 million, plus royalties, if certain milestones are met

Providence licenses mRNA technology to China's Everest in $100-million deal | Financial Post

Providence licenses mRNA technology to China's Everest in $100-million deal | Financial Post

The chief executive of a Canadian biotechnology firm that specializes in messenger RNA (mRNA) vaccines is slamming the federal government’s performance on the domestic COVID-19 vaccine front.

'Abysmal': Canadian vaccine maker slams feds on lack of support - BNN Bloomberg

Calgary-based company Providence Therapeutics has reached a deal with Emergent BioSolutions to produce mRNA vaccines at its Winnipeg facility.

Deal struck for Winnipeg facility to produce COVID-19 vaccine | Winnipeg Sun

Deal struck for Winnipeg facility to produce COVID-19 vaccine | Winnipeg Sun

Everest Medicines signed a licence agreement with Providence Therapeutics to make and sell the biotechnology company's potential mRNA COVID vaccines in some Asian countries. Everest Medicines signed a licence agreement with Providence Therapeutics to make and sell the biotechnology company's potential mRNA COVID vaccines in some Asian countries.

Everest to bring Canada’s Providence Therapeutics’ COVID-19 vaccine to China | Globalnews.ca

Emergent BioSolutions and Providence Therapeutics inked a five-year, $90 million deal for the contract drug manufacturer to support Providence’s development and manufacturing of its mRNA COVID-19 vaccine candidate.Emergent BioSolutions and Providence Therapeutics inked a five-year, $90 million deal for the contract drug manufacturer to support Providence’s development and manufacturing of its mRNA COVID-19 vaccine candidate.

Emergent, after J&J woes, inks $90M deal to help produce Providence Therapeutics' mRNA COVID-19 vaccine | FiercePharma

The Chinese mRNA sector is heating up. In the wake of megarounds by its compatriots, Everest Medicines has bought its way into the mRNA COVID-19 vaccine space through a deal with Providence Therapeutics.The Chinese mRNA sector is heating up. In the wake of megarounds by its compatriots, Everest Medicines has bought its way into the mRNA COVID-19 vaccine space through a deal with Providence Therapeutics.

Everest bags COVID-19 program in bid to conquer Chinese mRNA market | FierceBiotech

Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine, PTX-COVID19-B, and other mRNA vaccine candidates targeting specific variants in earlier stages of developmentEverest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.

Chinese Biopharma Strikes Deal with Western Company for COVID-19 Vaccine | BioSpace

Everest will gain rights to Providence's vaccine in Greater China and countries that include Indonesia, Singapore and Thailand.. Read more at straitstimes.com.Business News -Everest will gain rights to Providence's vaccine in Greater China and countries that include Indonesia, Singapore and Thailand.. Read more at straitstimes.com.

Chinese firm buys Canadian mRNA vaccine rights in $670 million deal, Business News & Top Stories - The Straits Times

www.theglobeandmail.com

While almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot

Chinese firm buys Canadian mRNA vaccine technology despite apparent resistance to western shots | Financial Post

Chinese firm buys Canadian mRNA vaccine technology despite apparent resistance to western shots | Financial Post

Bloomberg - Are you a robot?

Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

Emergent to make Providence Therapeutics potential COVID-19 vaccine | Reuters